about
Corresponding functional dynamics across the Hsp90 Chaperone family: insights from a multiscale analysis of MD simulationsModeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimerDrugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeuticsA comparison of Hsp90alpha and Hsp90beta interactions with cochaperones and substratesAnalysis of gene expression profile in colon cancer using the Cancer Genome Anatomy Project and RNA interference.Insights into radicicol biosynthesis via heterologous synthesis of intermediates and analogsThe interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitorsProbing molecular mechanisms of the Hsp90 chaperone: biophysical modeling identifies key regulators of functional dynamics.Effect of mutation of the tetratricopeptide repeat and asparatate-proline 2 domains of Sti1 on Hsp90 signaling and interaction in Saccharomyces cerevisiaeEfficient Synthesis of a Novel Resorcyclide as Anticancer Agent Based on Hsp90 InhibitionSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicDevelopment of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.Broad substrate specificity of the amide synthase in S. hygroscopicus--new 20-membered macrolactones derived from geldanamycin.Quinone reductases multitasking in the metabolic world.Reversing resistance to targeted therapy.Proteotoxic stress of cancer: implication of the heat-shock response in oncogenesis.Synthesis and antiviral activity of some novel indole-2-carboxylate derivatives.Multifocal angiostatic therapy: an update.Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.HSP90: a rising star on the horizon of anticancer targets.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.Novel interaction of the Hsp90 chaperone machine with Ssl2, an essential DNA helicase in Saccharomyces cerevisiae.Heat-shock proteins: new keys to the development of cytoprotective therapies.Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn's disease.Understanding ligand-based modulation of the Hsp90 molecular chaperone dynamics at atomic resolution.Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling.Heat shock proteins in antigen trafficking--implications on antigen presentation to T cells.Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.Merging chemical synthesis and biosynthesis: a new chapter in the total synthesis of natural products and natural product libraries.HSP90: chaperone-me-not.2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.New, non-quinone fluorogeldanamycin derivatives strongly inhibit Hsp90.Preparation of thermocleavable conjugates based on ansamitocin and superparamagnetic nanostructured particles by a chemobiosynthetic approach.Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.SGT1-HSP90 complex is required for CENP-A deposition at centromeres.Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities.Battling cancer on many fronts. Meeting on New Battlefields in Human Cancer--Attacking in Many Fronts.
P2860
Q27331720-2298228E-9C1C-4DF5-936C-FF9C88744FECQ27335863-957361F5-D1EE-43E0-B531-B2DFEF50B332Q28254233-E2F64DEC-C1E3-48D4-8561-685F6111F7F3Q28273877-1E7F616C-4E80-44A9-B88C-0976CDCCD33DQ33241373-C5FE8AAE-087D-460D-AB27-C19FEA17E81AQ34024374-62CEA5AB-04C2-4193-BBB8-A2D142483EB8Q34089152-15F4B58E-F7F6-4EAF-81B9-4609322EBBB7Q34248395-A815ED23-A831-4744-8733-F9D3FF68AF12Q34280087-9C3B9636-821B-4C60-BD2D-E084850B80B8Q34587324-FB4E8381-B006-4AAC-8770-AEF7A977BFE5Q34710940-4BBAA516-F312-46CF-88AA-64A478BA0A93Q34817365-4101D4CE-329E-4748-96B2-DE3FC874C374Q35127277-53E8A791-DD58-46D1-A735-76074055BA9FQ35797661-B9CD1032-3BBD-40FC-9052-6A2776C373B5Q35956182-03DAB786-294D-4626-8AD3-B4C86BA05936Q36028603-4BB83596-7FF9-41F5-8F3D-3779D7895090Q36200335-DE7C65C9-E9CE-4C9F-A5A8-56FE01F6E818Q36237540-DAB8AEE8-27AF-4902-B318-D87C7E27D78BQ36311166-3E5567F5-2031-4B6F-A059-0C51517CA4D7Q36429460-1824A32D-1C26-4D7C-B3E1-D1D6AB4ED966Q36429542-814754E2-9292-4979-A276-C1D2E6C70A29Q36429727-6C2D9DA8-F333-417A-916E-635E923BBD42Q36496582-2B9AD196-1918-4BED-8893-6FF1F0F3906CQ36596703-37D7F95E-8C0A-4D8F-9C39-D2C096E03479Q36627435-814CD379-6E63-494C-83F0-047775676CDAQ36685831-F29F6677-4AF2-4D93-B077-B13433418125Q36909273-DDD43867-136E-4EB4-82D3-1C04B7648CE7Q37529532-6A937719-CD3B-4DC8-8A97-4E3F1C9A97B8Q37622446-7FA95DCE-F1F3-45D7-BFBE-768A0B38E5FFQ37996334-C40D5F98-48BA-412F-80BD-01A972C93E95Q38125419-51EC6B40-A59F-4984-B586-EE7930FFACD3Q38785352-193AEE28-3049-453B-B491-72EA9548AB6DQ38922056-35DA0918-413B-4A75-A4DD-DBC49AF634C7Q38944991-1329AE5A-A1F7-4EAD-B5FB-80E25A334B42Q39986635-B2406CD4-A544-405D-82D4-F167FE380E09Q40346972-55A41121-0458-4E38-8349-42D15CF38B54Q40468950-9E3FA874-051F-4AD6-B921-2122FA55CB00Q41698562-B97CC85D-4B24-4279-AE2D-2973D2CA2041Q41856020-8430FACC-0E5B-43EC-A403-4B5DFAD73DA1Q42427012-44934AB5-8248-42B3-B8EC-E33A5946AC59
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Overview: translating Hsp90 biology into Hsp90 drugs.
@ast
Overview: translating Hsp90 biology into Hsp90 drugs.
@en
type
label
Overview: translating Hsp90 biology into Hsp90 drugs.
@ast
Overview: translating Hsp90 biology into Hsp90 drugs.
@en
prefLabel
Overview: translating Hsp90 biology into Hsp90 drugs.
@ast
Overview: translating Hsp90 biology into Hsp90 drugs.
@en
P356
P1476
Overview: translating Hsp90 biology into Hsp90 drugs.
@en
P304
P356
10.2174/1568009033481868
P50
P577
2003-10-01T00:00:00Z